{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:28:27Z","timestamp":1793093307465,"version":"4.5.0"},"reference-count":95,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10381","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T03:36:16Z","timestamp":1625283376000},"source":"Crossref","is-referenced-by-count":34,"title":["Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"Irena","family":"Pintea","sequence":"first","affiliation":[{"name":"Allergy Department, \u2018Professor Doctor Octavian Fodor\u2019 Regional Institute of Gastroenterology and Hepatology, 400000 Cluj\u2011Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Petricau","sequence":"additional","affiliation":[{"name":"Allergy Department, \u2018Professor Doctor Octavian Fodor\u2019 Regional Institute of Gastroenterology and Hepatology, 400000 Cluj\u2011Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu","family":"Dumitrascu","sequence":"additional","affiliation":[{"name":"Anatomy Discipline, \u2018Iuliu Hatieganu\u2019 University of Medicine and Pharmacy, 400000 Cluj\u2011Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Muntean","sequence":"additional","affiliation":[{"name":"Allergy Department, \u2018Professor Doctor Octavian Fodor\u2019 Regional Institute of Gastroenterology and Hepatology, 400000 Cluj\u2011Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Branisteanu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daciana","family":"Branisteanu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Grigore T. Popa\u2019 University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Deleanu","sequence":"additional","affiliation":[{"name":"Allergy Department, \u2018Professor Doctor Octavian Fodor\u2019 Regional Institute of Gastroenterology and Hepatology, 400000 Cluj\u2011Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"key20210812132855_b1-etm-0-0-10381","first-page":"1","article-title":"The role of national centers. Report of a WHO meeting","volume":"498","year":"1972","journal-title":"World Health Organ Tech Rep Ser"},{"key":"key20210812132855_b2-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1398-9995.2008.01944.x","article-title":"Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project","volume":"64","author":"Bousquet","year":"2009","journal-title":"Allergy"},{"key":"key20210812132855_b3-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"key20210812132855_b4-etm-0-0-10381","author":"Rawlins"},{"key":"key20210812132855_b5-etm-0-0-10381","author":"Thong"},{"key":"key20210812132855_b6-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.mcna.2010.03.001","article-title":"The complex clinical picture of side effects to biologicals","volume":"94","author":"Hausmann","year":"2010","journal-title":"Med Clin North Am"},{"key":"key20210812132855_b7-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"key20210812132855_b8-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Sunthralingam","year":"2006","journal-title":"N Engl J Med"},{"key":"key20210812132855_b9-etm-0-0-10381","first-page":"873","article-title":"OKT3-induced cytokine-release syndrome: Occurrence beyond the second dose and association with rejection severity","volume":"27","author":"Vasquez","year":"1995","journal-title":"Transplant Proc"},{"key":"key20210812132855_b10-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/15476910801897433","article-title":"Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction","volume":"5","author":"Wing","year":"2008","journal-title":"J Immunotoxicol"},{"key":"key20210812132855_b11-etm-0-0-10381","first-page":"250","article-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","volume":"72","author":"Cheifetz","year":"2005","journal-title":"Mt Sinai J Med"},{"key":"key20210812132855_b12-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/s0140-6736(95)90963-x","article-title":"Polysorbate 80 hypersensitivity","volume":"345","author":"Shelley","year":"1995","journal-title":"Lancet"},{"key":"key20210812132855_b13-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1440-1797.2005.00389.x","article-title":"Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin","volume":"10","author":"Steele","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"key20210812132855_b14-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","article-title":"Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy","volume":"28","author":"Price","year":"2007","journal-title":"Allergy Asthma Proc"},{"issue":"9","key":"key20210812132855_b15-etm-0-0-10381","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0327-4","article-title":"Immediate hypersensitivity to polyethylene glycols in unrelated products: When standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary","volume":"15","author":"Jover Cerd\u00e1","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"key20210812132855_b16-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key20210812132855_b17-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.clinthera.2010.07.021","article-title":"Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing","volume":"32","author":"Stubenrauch","year":"2010","journal-title":"Clin Ther"},{"key":"key20210812132855_b18-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 Desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"key20210812132855_b19-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"key20210812132855_b20-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40259-013-0066-x","article-title":"Drug desensitization in the management of allergy and anaphylaxis to chemotherapeutic agents and monoclonal antibodies","volume":"28","author":"Mezzano","year":"2013","journal-title":"BioDrugs"},{"key":"key20210812132855_b21-etm-0-0-10381","first-page":"343","article-title":"Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection","volume":"66","author":"Georgitis","year":"1991","journal-title":"Ann Allergy"},{"issue":"955","key":"key20210812132855_b22-etm-0-0-10381","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03423.x","article-title":"Transfusion medicine illustrated. Monoclonal antibody-stimulated serum sickness","volume":"44","author":"Proctor","year":"2004","journal-title":"Transfusion"},{"issue":"21","key":"key20210812132855_b23-etm-0-0-10381","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics-the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"key":"key20210812132855_b24-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2165\/00003495-200464160-00004","article-title":"Managing immunogenic responses to infliximab: Treatment implications for patients with Crohn's disease","volume":"64","author":"Han","year":"2004","journal-title":"Drugs"},{"key":"key20210812132855_b25-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20210812132855_b26-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"key20210812132855_b27-etm-0-0-10381","first-page":"31","article-title":"Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response","volume":"33","author":"Haraoui","year":"2006","journal-title":"J Rheumatol"},{"key":"key20210812132855_b28-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b29-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b30-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"351210","key":"key20210812132855_b31-etm-0-0-10381","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/351210","article-title":"Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: Pathophysiology and management","volume":"2012","author":"Abdullah","year":"2012","journal-title":"Chemother Res Pract"},{"key":"key20210812132855_b32-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1212\/WNL.0000000000005854","article-title":"Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy","volume":"91","author":"Rauer","year":"2018","journal-title":"Neurology"},{"key":"key20210812132855_b33-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/annrheumdis-2017-211169","article-title":"Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-Year data of the DRESS study-a randomised controlled pragmatic non-inferiority strategy trial","volume":"76","author":"Bouman","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b34-etm-0-0-10381","author":"Shah"},{"key":"key20210812132855_b35-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/annonc\/mdx640","article-title":"Stevens-Johnson syndrome during nivolumab treatment of NSCLC","volume":"29","author":"Salati","year":"2018","journal-title":"Ann Oncol"},{"key":"key20210812132855_b36-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20210812132855_b37-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annder.2016.11.012","article-title":"Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome","volume":"144","author":"Demirtas","year":"2017","journal-title":"Ann Dermatol Venereol"},{"key":"key20210812132855_b38-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20210812132855_b39-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1078155214533368","article-title":"Fatal Stevens-Johnson syndrome\/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy","volume":"21","author":"Fallon","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"key20210812132855_b40-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/ajd.12594","article-title":"Acute localised exanthematous pustulosis secondary to pembrolizumab","volume":"58","author":"Wang","year":"2017","journal-title":"Australas J Dermatol"},{"key":"key20210812132855_b41-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.3892\/ol.2019.10071","article-title":"Synthesis and physiological implications of melanic pigments","volume":"17","author":"Maranduca","year":"2019","journal-title":"Oncol Lett"},{"key":"key20210812132855_b42-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/CMR.0000000000000261","article-title":"Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"key20210812132855_b43-etm-0-0-10381","first-page":"1217","article-title":"An unusual cutaneous malignant melanoma arised de novo: A case report","volume":"56","author":"Blendea","year":"2015","journal-title":"Rom J Morphol Embryol"},{"key":"key20210812132855_b44-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-4632.2011.05002.x","article-title":"Varicella like generalized pustulosis induced by adalimumab","volume":"52","author":"Suga","year":"2013","journal-title":"Int J Dermatol"},{"key":"key20210812132855_b45-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1742-481X.2011.00799.x","article-title":"Acute generalised exanthematous pustulosis following intravitreal Ranibizumab","volume":"8","author":"Bosanquet","year":"2011","journal-title":"Int Wound J"},{"key":"key20210812132855_b46-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"key20210812132855_b47-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20210812132855_b48-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.idc.2010.01.006","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"24","author":"Koo","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"key20210812132855_b49-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b50-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1136\/ard.2007.071878","article-title":"Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab","volume":"66","author":"Gelinck","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"13030\/qt58j4n38m","key":"key20210812132855_b51-etm-0-0-10381","article-title":"Tuberculosis and interleukin blocking monoclonal antibodies: Is there risk?","volume":"24","author":"Kelsey","year":"2018","journal-title":"Dermatol Online J"},{"key":"key20210812132855_b52-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: A double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"key20210812132855_b53-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"key20210812132855_b54-etm-0-0-10381","first-page":"1054","article-title":"Double irradiation for macroscopic radioresistance or recurrence of melanomas of the posterior uvea: Clinical, ballistic, therapeutic and prognostic aspects: Series of 19 cases among 462 patients","volume":"22","author":"Grange","year":"1999","journal-title":"J Fr Ophtalmol"},{"issue":"40","key":"key20210812132855_b55-etm-0-0-10381","article-title":"Options and therapy limits in a case of severe psoriasis","volume":"24","author":"Br\u0103ni\u015fteanu","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20210812132855_b56-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"11","DOI":"10.15570\/actaapa.2017.3","article-title":"Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice","volume":"26","author":"Khobzey","year":"2017","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"key20210812132855_b57-etm-0-0-10381","first-page":"38","article-title":"Adverse reactions of biological therapy for psoriasis","volume":"119","author":"Br\u0103ni\u015fteanu","year":"2015","journal-title":"Rev Med Chir Soc Med Nat"},{"key":"key20210812132855_b58-etm-0-0-10381","first-page":"57","article-title":"A review of neurologic complications of biologic therapy in plaque psoriasis","volume":"101","author":"Lin","year":"2008","journal-title":"Cutis"},{"key":"key20210812132855_b59-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2337\/dc10-2274","article-title":"Type 1 diabetes and interferon therapy: A nationwide survey in Japan","volume":"34","author":"Nakamura","year":"2011","journal-title":"Diabetes Care"},{"key":"key20210812132855_b60-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3748\/wjg.v21.i1.233","article-title":"Interferon therapy in hepatitis C leading to chronic type 1 diabetes","volume":"21","author":"Zornitzki","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key20210812132855_b61-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b62-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key20210812132855_b63-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","article-title":"The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Dommasch","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key20210812132855_b64-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20210812132855_b65-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1097\/MEG.0b013e32834bb90a","article-title":"Hepatosplenic T-cell lymphoma in patients receiving TNF-\u03b1 inhibitor therapy: Expanding the groups at risk","volume":"23","author":"Parakkal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20210812132855_b66-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","article-title":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: A European registries collaborative project","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b67-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: Is there a silver lining?","volume":"23","author":"Per\u00e9z-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20210812132855_b68-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"key20210812132855_b69-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semarthrit.2009.09.001","article-title":"Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk","volume":"40","author":"Khasnis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"key20210812132855_b70-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British society for rheumatology biologics register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20210812132855_b71-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"key20210812132855_b72-etm-0-0-10381","first-page":"770","article-title":"Ethiopatogenic hypotheses in lichen planus","volume":"120","author":"Br\u0103ni\u015fteanu","year":"2016","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"key20210812132855_b73-etm-0-0-10381","first-page":"S817","article-title":"Histopathological and clinical traps in lichen sclerosus: A case report","volume":"57 (Suppl 2)","author":"Br\u0103ni\u015fteanu","year":"2016","journal-title":"Rom J Morphol Embryol"},{"key":"key20210812132855_b74-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"key20210812132855_b75-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"key20210812132855_b76-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2011.06.050","article-title":"T-cell involvement in delayed-type hypersensitivity reactions to infliximab","volume":"128","author":"Torres","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1316","key":"key20210812132855_b77-etm-0-0-10381","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061316","article-title":"Drug hypersensitivity and desensitizations: Mechanisms and new approaches","volume":"18","author":"de Las Vecillas S\u00e1nchez","year":"2017","journal-title":"Int J Mol Sci"},{"key":"key20210812132855_b78-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000490419","article-title":"Effective desensitization to tocilizumab in delayed hypersensitivity reaction","volume":"102","author":"Cortellini","year":"2018","journal-title":"Pharmacology"},{"key":"key20210812132855_b79-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.anai.2011.03.014","article-title":"Adalimumab desensitization after anaphylactic reaction","volume":"106","author":"Quercia","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key20210812132855_b80-etm-0-0-10381","first-page":"443","article-title":"Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization","volume":"65","author":"Pruzansky","year":"1988","journal-title":"Immunology"},{"key":"key20210812132855_b81-etm-0-0-10381","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.139.2.501","article-title":"Basic characteristics of human lung mast cell desensitization","volume":"139","author":"MacGlashan","year":"1987","journal-title":"J Immunol"},{"key":"key20210812132855_b82-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000335637","article-title":"Desensitization for hypersensitivity reactions to medications","volume":"97","author":"del Carmen Sancho","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"key20210812132855_b83-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaci.2013.02.004","article-title":"Successful rapid rituximab desensitization in an adolescent patient with nephrotic syndrome: Increase in number of Treg cells after desensitization","volume":"132","author":"Aydogan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"key20210812132855_b84-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jaci.2004.08.037","article-title":"Loss of syk kinase during IgE-mediated stimulation of human basophils","volume":"114","author":"Macglashan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"key20210812132855_b85-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"352","DOI":"10.18176\/jiaci.0288","article-title":"Successful desensitization to brentuximab after anaphylactic shock","volume":"28","author":"G\u00f6rg\u00fcl\u00fc","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"key":"key20210812132855_b86-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.jaip.2017.11.033","article-title":"Outcome of 490 desensitizations to chemotherapy drugs with a rapid one-solution protocol","volume":"6","author":"P\u00e9rez-Rodr\u00edguez","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key20210812132855_b87-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biologicals.2018.07.002","article-title":"Successful slow tocilizumab desensitization in a patient with adult onset Still disease","volume":"55","author":"Erdogan","year":"2018","journal-title":"Biologicals"},{"key":"key20210812132855_b88-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000454808","article-title":"rapid drug desensitization with biologics: A single-center experience with four biologics","volume":"171","author":"Bavbek","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"key20210812132855_b89-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis-a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key20210812132855_b90-etm-0-0-10381","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40521-020-00238-y","article-title":"Importance of diagnostics prior to desensitization in new drug hypersensitivity: Chemotherapeutics and biologicals","volume":"7","author":"Madrigal-Burgaleta","year":"2020","journal-title":"Curr Treat Options Allergy"},{"key":"key20210812132855_b91-etm-0-0-10381","first-page":"55","article-title":"Erythema multiforme-etiopathogenic, clinical and therapeutic aspects","volume":"119","author":"Cre\u0163u","year":"2015","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"key20210812132855_b92-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"key20210812132855_b93-etm-0-0-10381","first-page":"327","article-title":"Diagnosis and management of hypersensitivity reactions caused by oxaliplatin","volume":"16","author":"Herrero","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"key20210812132855_b94-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1081-1206(10)60247-5","article-title":"Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization","volume":"102","author":"Breslow","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key20210812132855_b95-etm-0-0-10381","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaip.2013.08.009","article-title":"Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels","volume":"2","author":"Ojaimi","year":"2014","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T12:19:55Z","timestamp":1672661995000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":95,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,3]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10381","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"article-number":"949"}}